A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases

• Inclusion Criteria:

1. Subjects voluntary agreement to provide written informed consent.

2. Aged 18 to 70 years, either sex.

3. Clinical laboratory values meet screening criteria.

4. Positive test for CD19 and/ or BCMA

SLE:

• Meets at least 1 classification criteria≥6 months for SLE.

• At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Smithantibody should be positive.

• Fulfill relapsed/refractory SLE conditions.

AAV:

• Meets the 2022 ACR/EULAR classification criteria for AAV.

• Positive test for anti-MPO or p-ANCA or anti-PR3 or anti-MPO antibodies atscreening.

• Fulfill relapsed/refractory AAV conditions.

SSc:

• Meets the 2013 ACR/EULAR classification criteria for SSc.

• At screening, mRSS is higher than 10.

• Fulfill relapsed/refractory SSc conditions.

IIM:

• Meets 2017 EULAR/ACR classification criteria for IIM.

• Positive test for myositis-associated antibodies or myositis-specific antibodies atscreening.

• Fulfill relapsed/refractory IIM conditions. SjS：

• Meets the 2016 ACR/EULAR diagnostic criteria for SjS.

• Positive test for anti-SSA and/or anti-SSB antibodies at screening.

• Fulfill relapsed/refractory SjS conditions.

Exclusion Criteria:

1. Active infections such as hepatitis and tuberculosis.

2. Other autoimmune diseases.

3. Serious underlying diseases such as tumor, uncontrolled diabetes.

4. Female subjects who were pregnant, breastfeeding.

5. Those with a history of major organ transplantation.

6. Have received autologous cell therapy of any target before.